NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1 to 25 of 1203

Display Results as:

Biology Of Aging Dental, Oral And Craniofacial Tissues (R21 - Clinical Trial Not Allowed) - RFA-DE-18-010

Organization: NIDCR 

Posting Date: 09-19-2017 

Expiration Date: 03-01-2018 

Activity Code: R21 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate collaborative research to understand the biological mechanisms of aging in dental, oral, and craniofacial (DOC) tissues, as they relate to parallel processes in other tissues and organs. The areas of emphasis under this FOA include inflammation, tissue healing and regeneration, and epigenetic regulation. The overarching long-term goal of this effort is to improve oral health in older adults by addressing knowledge gaps in our understanding of the basic biology of age-associated changes in health and disease states of DOC tissues.  

Biology Of Aging Dental, Oral And Craniofacial Tissues (R01 - Clinical Trial Not Allowed) - RFA-DE-18-009

Organization: NIDCR 

Posting Date: 09-19-2017 

Expiration Date: 03-01-2018 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate collaborative research to understand the biological mechanisms of aging in dental, oral, and craniofacial (DOC) tissues, as they relate to parallel processes in other tissues and organs. The areas of emphasis under this FOA include inflammation, tissue healing and regeneration, and epigenetic regulation. The overarching long-term goal of this effort is to improve oral health in older adults by addressing knowledge gaps in our understanding of the basic biology of age-associated changes in health and disease states of DOC tissues.  

Developmental Centers for Interdisciplinary Research in Benign Urology (P20 - Clinical Trials Not Allowed) - RFA-DK-17-033

Organization: NIDDK 

Posting Date: 10-06-2017 

Expiration Date: 03-01-2018 

Activity Code: P20 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Developmental Centers for Interdisciplinary Research in Benign Urology Program (P20). Among the goals of this Program is to further advance research in benign urology by building research teams and facilitating resources generation and sharing. The research teams should be composed of individuals with complementary expertise who propose to either develop innovative resources (Resource Development Projects) or a new research project (Scientific Research Projects) that utilize integrative approaches to address questions relevant to benign urological diseases or disorders. Patient-centered research is encouraged. Resources developed by the Resource Development Projects will be shared upon validation while resources developed within the Scientific Research Projects will be shared at the end or termination of the award, as appropriate and consistent with the program goal of further advancing research. Each Developmental Center is centered on a single Project and must contain an Administrative Core and an Educational Enrichment Program. As part of the efforts of the Division of Kidney, Urologic and Hematologic Diseases (DKUH) to expand and enhance benign urology research, the Developmental Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe) Career Development Program.  

Research on Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Health Disparity Populations (R01-Clinical Trial Not Allowed) - RFA-MD-18-003

Organization: NIMHD 

Posting Date: 11-30-2017 

Expiration Date: 03-01-2018 

Activity Code: R01 

Summary: The purpose of this initiative is to support community-based and healthcare setting-based research to understand the individual, interpersonal, community and societal factors that influence patterns of PrEP attitudes, access, availability, and adherence among health disparity populations in the US. Projects may involve primary quantitative/qualitative data collection and/or secondary analysis of existing data. 

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01) - PAR-15-120

Organization: NIDA 

Posting Date: 02-13-2015 

Expiration Date: 03-02-2018 

Activity Code: U01 

Summary: The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping. This FOA will replace PAR-14-010 "Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3)" 

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed) - PA-18-496

Organization: NCI 

Posting Date: 12-15-2017 

Expiration Date: 03-02-2018 

Activity Code: (Admin Supp) 

Summary: This administrative supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials. 

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) - (Clinical Trials Not Allowed) - RFA-HL-18-026

Organization: NHLBI 

Posting Date: 10-26-2017 

Expiration Date: 03-03-2018 

Activity Code: K01 

Summary: This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. 

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) (Clinical Trial Required) - RFA-HL-18-027

Organization: NHLBI 

Posting Date: 11-09-2017 

Expiration Date: 03-03-2018 

Activity Code: K01 

Summary: This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. 

Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trials Not Allowed) - RFA-RM-17-025

Organization: OSC 

Posting Date: 12-18-2017 

Expiration Date: 03-03-2018 

Activity Code: UG3/UH3 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UH2 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of initial production level data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution. 

Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed) - RFA-RM-17-027

Organization: OSC 

Posting Date: 12-18-2017 

Expiration Date: 03-03-2018 

Activity Code: U54 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, multi-parameter maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with micron resolution. 

AHRQ Health Services Research Projects: Making Health Care Safer in Ambulatory Care Settings and Long Term Care Facilities (R01) - PA-15-339

Organization: AHRQ 

Posting Date: 08-28-2015 

Expiration Date: 03-06-2018 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to support investigative research projects that examine the epidemiology of patient safety in ambulatory care settings and long term care facilities, gather evidence about strategies that can improve safety in these settings, and develop evidence-based tools to facilitate implementation of these strategies. 

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed) - PA-18-517

Organization: NCI 

Posting Date: 12-19-2017 

Expiration Date: 03-06-2018 

Activity Code: (Admin Supp) 

Summary: This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying. 

Bridges to the Baccalaureate (R25) - PAR-16-110

Organization: NIGMS 

Posting Date: 02-22-2016 

Expiration Date: 03-08-2018 

Activity Code: R25 

Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Curriculum or Methods Development. A proposed program must include each activity and describe how they will be integrated. 

Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) - PAR-15-330

Organization: NIAID 

Posting Date: 08-14-2015 

Expiration Date: 03-10-2018 

Activity Code: U19 

Summary: The goal of the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials.A preclinical research application alone is not sufficient for this announcement.Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the project period of the award.However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies by the end of the award. 

Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01- Clinical Trial Optional) - RFA-DK-17-038

Organization: NIDDK 

Posting Date: 11-09-2017 

Expiration Date: 03-14-2018 

Activity Code: R01 

Summary: The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection and epidemiological studies of liver diseases and disorders in HIV patients. 

Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01 Clinical Trial Optional) - RFA-DK-17-036

Organization: NIDDK 

Posting Date: 11-21-2017 

Expiration Date: 03-14-2018 

Activity Code: R01 

Summary: The goal of this Funding Opportunity Announcement (FOA) is to support innovative research to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. This FOA supports both mechanistic research and clinical trials. Proposed projects must be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK). 

Innovative Research in HIV in Kidney, Urology, and Hematology (R01 Clinical Trial Optional) - RFA-DK-17-037

Organization: NIDDK 

Posting Date: 11-28-2017 

Expiration Date: 03-14-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications for innovative research projects examining the basic and clinical aspects of HIV infection, treatment, and long-term sequelae as they relate to the mission of the Division of Kidney, Urologic and Hematologic Diseases within NIDDK (KUH/NIDDK). 

The Role of the Microbiome in the Developmental Origins of Health and Disease (DOHaD) (R01 Clinical Trial Not Allowed) - RFA-ES-18-005

Organization: NIEHS 

Posting Date: 11-21-2017 

Expiration Date: 03-15-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) seeks innovative research proposals that use animal models to investigate the potential role of the microbiome in mediating the latent effects of early life exposure. 

Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed) - RFA-AI-17-039

Organization: NIAID 

Posting Date: 12-04-2017 

Expiration Date: 03-15-2018 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to identify changes in immune mechanisms and markers because of Mycobacterium tuberculosis (Mtb) exposure, infection or disease in pediatric populations exposed to or infected with HIV-1. 

BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 - Clinical Trial Not Allowed) - RFA-NS-18-009

Organization: NINDS 

Posting Date: 10-04-2017 

Expiration Date: 03-16-2018 

Activity Code: R01 

Summary: This FOA solicits applications for research projects that use innovative and methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human animal species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior. 

Pediatric Device Consortia Grants Program (P50) - RFA-FD-18-004

Organization: FDA 

Posting Date: 01-12-2018 

Expiration Date: 03-16-2018 

Activity Code: P50 

Summary: The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA's Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generation of devices. In addition, consortia should also provide expertise on evidence generation, including use of real world evidence, for pediatric device development. The pediatric population (i.e., neonates, infants, children, and adolescents) for medical devices is defined as individuals who are younger than 22 years of age (that is, from birth through the twenty-first year of life not including the twenty-second birthday) at the time of diagnosis or treatment. 

Data Science Research: Personal Health Libraries for Consumers and Patients (R01) - PAR-17-159

Organization: NLM 

Posting Date: 02-08-2017 

Expiration Date: 03-20-2018 

Activity Code: R01 

Summary: The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing.  

Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 Clinical Trial Optional) - RFA-AI-17-028

Organization: NIAID 

Posting Date: 09-12-2017 

Expiration Date: 03-20-2018 

Activity Code: R61/R33 

Summary: The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs. MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA. 

Discovery and Biological Signatures of Diet Derived Microbial Metabolites (R01 Clinical Trial Optional) - RFA-AT-18-003

Organization: NCCIH  (formerly NCCAM)

Posting Date: 12-15-2017 

Expiration Date: 03-20-2018 

Activity Code: R01 

Summary: Evidence is building that low molecular weight compounds, derived from interaction of dietary constituents and other natural products with the microbiome, have important biological activity in animal models. This initiative seeks to characterize the compounds produced by microbial metabolism of dietary phytochemicals, identify the commensal bacteria responsible for their production and establish the biological signatures that define their interaction with a biological system. 

Planning Grant to Develop Phase III Clinical Trials for Lewy Body Dementia (R34 clinical Trial Not Allowed) - RFA-NS-18-017

Organization: NINDS 

Posting Date: 12-06-2017 

Expiration Date: 03-21-2018 

Activity Code: R34 

Summary: The purpose of this R34 FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top